NF-κB in Hematological Malignancies
AbstractNF-κB (Nuclear Factor Κ-light-chain-enhancer of activated B cells) transcription factors are critical regulators of immunity, stress response, apoptosis, and differentiation. Molecular defects promoting the constitutive activation of canonical and non-canonical NF-κB signaling pathways contribute to many diseases, including cancer, diabetes, chronic inflammation, and autoimmunity. In the present review, we focus our attention on the mechanisms of NF-κB deregulation in hematological malignancies. Key positive regulators of NF-κB signaling can act as oncogenes that are often prone to chromosomal translocation, amplifications, or activating mutations. Negative regulators of NF-κB have tumor suppressor functions, and are frequently inactivated either by genomic deletions or point mutations. NF-κB activation in tumoral cells is also driven by the microenvironment or chronic signaling that does not rely on genetic alterations. View Full-Text
Share & Cite This Article
Imbert, V.; Peyron, J.-F. NF-κB in Hematological Malignancies. Biomedicines 2017, 5, 27.
Imbert V, Peyron J-F. NF-κB in Hematological Malignancies. Biomedicines. 2017; 5(2):27.Chicago/Turabian Style
Imbert, Véronique; Peyron, Jean-François. 2017. "NF-κB in Hematological Malignancies." Biomedicines 5, no. 2: 27.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.